Patents
Literature
50 results about "HLA Complex" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A family of proteins that are essential for the presentation of peptide antigens on cell surfaces that modulate the host defensive activities of T-cells. This protein family includes major histocompatibility complex (MHC) class I and class II proteins.
Soluble TCR molecules and methods of use
ActiveUS20050214284A1Reduced lung metastasisGreat cancer therapeuticImmunoglobulin superfamilyAntibody mimetics/scaffoldsPeptide antigenCancer cell
Disclosed are compositions and methods for detecting cells or tissue comprising a peptide antigen presented in the context of an MHC or HLA complex. The invention has a wide range of applications including providing a highly sensitive method for detecting cancer cells.
Owner:ALTOR BIOSCIENCE CORP
T cell receptor having binding affinity for a peptide-MHC complex and uses thereof
InactiveUS8906383B2Enhanced interactionStructure miniaturizationBacteriaPeptide/protein ingredientsT-Cell Receptor BetaPreproinsulin
The present disclosure provides isolated preproinsulin-derived peptides of 8 or 9 amino acids, comprising the amino acid sequence WGPDPAA (SEQ ID NO: 1), isolated Class I peptide-HLA complexes presenting said peptides and isolated molecules having binding affinity for said peptides and / or said peptide-HLA complexes. Such compositions are useful in the treatment of type 1 diabetes mellitus (T1DM). Such isolated molecules can include a T cell receptor (TCR) having specific binding affinity for a peptide-MHC complex wherein the MHC is an HLA Class I molecule and the peptide is a preproinsulin-derived peptide of 8 to 10 amino acids, comprising the amino acid sequence WGPDPAA (SEQ ID NO: 1).
Owner:KINGS COLLEGE LONDON
Hla-restricted epitopes encoded by somatically mutated genes
InactiveUS20180086832A1Raise the ratioPolypeptide with localisation/targeting motifAntibody mimetics/scaffoldsWild typeCancer research
Mutant epitopes encoded by cancer genes are virtually always located in the interior of cells, making them invisible to conventional antibodies. We generated single chain variable fragments (scFvs) specific for mutant peptides presented on the cell surface by human leukocyte antigen (HLA) molecules. These scFvs can be converted to full-length antibodies, termed MANAbodies, targeting “Mutation Associated Neo-Antigens” bound to HLA. A phage display library representing a highly diverse array of single-chain variable fragment sequences was first designed and constructed. A competitive selection protocol was then used to identify clones specific for peptides bound to pre-defined HLA types. In this way, we obtained scFvs, including one specific for a peptide encoded by a common KRAS mutant and another by a common EGFR mutant. Molecules targeting MANA can be developed that specifically react with mutant peptide-HLA complexes even when these peptides differ by only one amino acid from the normal, wild-type form.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
HPV vaccine comprising peptides from host cell proteins
The present invention relates to a human papillomavirus (HPV) vaccine that comprises peptides from host cell proteins and more particularly, a vaccine that is directed against cancers that are associated with HPV infections, such as cervical cancer, head and neck cancer and skin cancers. The peptides comprise fragments of host cell proteins that have been targeted for degradation by HPV proteins, such as E6 and E7 and are presented on the surface of HPV infected cells in relatively large amounts. These peptides can be recognised by CTL and elicit an immune response, and are therefore ideal tumour-specific markers. The invention also relates to novel peptide: peptide complexes such as peptide / HLA complexes and their use in a tumour-specific vaccine.
Owner:UNIV COLLEGE CARDIFF CONSULTANTS LTD
Hla-restricted epitopes encoded by somatically mutated genes
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
HPV vaccine comprising peptides from host cell proteins
The present invention relates to an immunogenic composition for a human papillomavirus (HPV) vaccine that comprises BAX peptides from BAX host cell proteins and more particularly, a vaccine including those peptides that is directed against cancers that are associated with HPV infections, such as cervical cancer, head and neck cancer and skin cancers. The BAX peptides comprise fragments of BAX host cell proteins that have been targeted for degradation by HPV proteins, such as E6 and E7 and are presented on the surface of HPV infected cells in relatively large amounts. These peptides can be recognised by CTL and elicit an immune response, and are therefore ideal tumour-specific markers. The invention also relates to novel peptide: peptide complexes such as BAX peptide / HLA complexes and their use in a tumour-specific vaccine.
Owner:UNIV COLLEGE CARDIFF CONSULTANTS LTD
Assay kit for detecting human leukocyte antigen-B (HLA-B)*57:01 and HLA complex P5 (HCP5) alleles
InactiveCN103215356ASave operating timeSave operating workloadMicrobiological testing/measurementDNA/RNA fragmentationAgricultural scienceGenotype
The invention discloses an assay kit for detecting human leukocyte antigen-B (HLA-B)*57:01 and HLA complex P5 (HCP5) alleles. The assay kit comprises a polymerase chain reaction (PCR) reaction liquid containing primers for detecting HLA-B*57:01 and HCP5, wherein the primers for detecting HLA-B*57:01 are primers B57F, B57R1 and B57R2; the primer B57F has a sequence shown in SEQIDNO:1, the primer B57R1 has a sequence shown in SEQIDNO:2, and the primer B57R2 has a sequence shown in SEQIDNO:3; and the primers for detecting the HCP5 are primers 631R and 568GF, wherein the primer 631R has a sequence shown in SEQIDNO:4, and the primer 568GF has a sequence shown in SEQIDNO:5. The assay kit has high detection sensitivity and good specificity, and can be used for accurately separating genotypes without sequencing.
Owner:上海血液生物医药有限责任公司
Peptide-hla complexes and methods of producing same
ActiveUS20190345222A1Natural folding and/or glycosylation of the proteinLow costPolypeptide with localisation/targeting motifGenetically modified cellsPeptideHLA Complex
There is provided herein, the use of mammalian derived HLA class I molecule for in vitro peptide exchange. For example, there is provided a method of producing an HLA class I molecule complexed to a pre-selected peptide comprising: (a) providing a mammalian derived HLA class I molecule complexed to an existing peptide; (b) incubating, in vitro, the HLA class I molecule complexed to the existing peptide with the pre-selected peptide, wherein the pre-selected peptide is at a concentration sufficient to replace the existing peptide to produce the HLA class I molecule complexed to the pre-selected peptide; and the HLA class I molecule comprises a1, a1, a2, a3 and β2m domains.
Owner:UNIV HEALTH NETWORK
Tumor antigens and CTL clones isolated by a novel procedure
InactiveUS7351409B2Effective isolationReduced activityBiocideTumor rejection antigen precursorsT lymphocyteTumor antigen
The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide / HLA complexes which are recognized by the isolated CTL clones.
Owner:LUDWIG INST FOR CANCER RES
Method for identifying HLA complexes associated with adverse drug reactions
InactiveUS20110251074A1Library member identificationMaterial analysisADR - Adverse drug reactionBioinformatics
A method for identifying from an HLA library an HLA complex that specifically binds to a compound. This method can be relied on to assess whether a compound is likely to induce an adverse drug reaction and, if so, in which human population.
Owner:NATIONAL YANG MING UNIVERSITY
Binding proteins and engineered cells specific for neoantigens and uses thereof
The present disclosure provides compositions and methods for targeting neoantigens, for example, to treat or prevent cancer. The disclosed embodiments include binding proteins, such as T cell receptors, that bind to the neoantigen: HLA complex. The binding protein further comprises a construct comprising a fusion protein of the CD95 extracellular domain and the CD137 intracellular signaling domain (Fas-41BB), and a CDS coreceptor alpha or beta chain. The disclosed binding proteins are highly sensitive to antigens and are capable of inducing activation of host T cells at low concentrations of peptide antigens. In certain embodiments, binding proteins of the present disclosure (i) have no alloreactivity, substantially no alloreactivity, and / or low risk of alloreactivity, to amino acid sequences from human proteomes and / or (ii) to human HLA alleles. Polynucleotides encoding such binding proteins can be introduced into host cells, such as T cells, and the cells can be used in immunotherapy for the treatment of various cancers.
Owner:AIFENI T MEDICAL +1
Binding proteins specific for ras neoantigens and uses thereof
PendingUS20250114433A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyCancer preventionAntigen receptors
The present disclosure provides compositions and methods for targeting a Ras antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as a T cell receptor or a chimeric antigen receptor, that bind to a Ras antigen:HLA complex. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers. Also provided are immunogenic polypeptides that can be useful to, for example, induce an immune response against a mutated Ras or to identify a binding protein that binds to a Ras antigen.
Owner:FRED HUTCHINSON CANCER CENT
Soluble TCR molecules and methods of use
ActiveUS8772451B2Reduced flexibilityReduce sensitivityAntibody mimetics/scaffoldsNanomedicinePeptide antigenCancer cell
Disclosed are compositions and methods for detecting cells or tissue comprising a peptide antigen presented in the context of an MHC or HLA complex. The invention has a wide range of applications including providing a highly sensitive method for detecting cancer cells.
Owner:ALTOR BIOSCIENCE CORP
HPV vaccine comprising peptides from host cell proteins
InactiveUS7538183B2Peptide/protein ingredientsSnake antigen ingredientsInfected cellHuman papillomavirus
Owner:UNIV COLLEGE CARDIFF CONSULTANTS LTD
Human immunodeficiency virus-specific T cell receptors
ActiveUS12325734B2Polypeptide with localisation/targeting motifImmunoglobulin superfamilyImmunity responseHiv infected
Engineered TCR molecules specific to retroviral peptide / HLA complexes guide direct killing and / or enable robust immune responses against HIV infected cells. In a first aspect, a TCR fusion polypeptide comprises a TCR variable alpha (Vα) domain, a TCR variable beta domain (Vβ) and a TCR constant region domain (C), wherein the TCR fusion polypeptide is specific for HIV peptides.
Owner:ALTOR BIOSCIENCE LLC +1
HPV vaccine comprising peptides from host cell proteins
The present invention relates to an immunogenic composition for a human papillomavirus (HPV) vaccine that comprises BAX peptides from BAX host cell proteins and more particularly, a vaccine including those peptides that is directed against cancers that are associated with HPV infections, such as cervical cancer, head and neck cancer and skin cancers. The BAX peptides comprise fragments of BAX host cell proteins that have been targeted for degradation by HPV proteins, such as E6 and E7 and are presented on the surface of HPV infected cells in relatively large amounts. These peptides can be recognised by CTL and elicit an immune response, and are therefore ideal tumour-specific markers. The invention also relates to novel peptide: peptide complexes such as BAX peptide / HLA complexes and their use in a tumour-specific vaccine.
Owner:UNIV COLLEGE CARDIFF CONSULTANTS LTD
Binding proteins specific for ras neoantigen and uses thereof
PendingCN119522236APolypeptide with localisation/targeting motifImmunoglobulin superfamilyPeptide antigenProteinoid
The present disclosure provides compositions and methods for targeting Ras antigens, for example, to treat or prevent cancer. The disclosed embodiments include binding proteins, such as T cell receptors that bind to the Ras antigen: HLA complex. The disclosed binding proteins are highly sensitive to antigens, which binding proteins are capable of inducing activation of host T cells at low concentrations of peptide antigens. In certain embodiments, binding proteins of the present disclosure are non-alloreactive, substantially non-alloreactive, and / or alloreactivity with a lower risk against (i) amino acid sequences from human proteomes and / or (ii) human HLA alleles. Polynucleotides encoding such binding proteins can be introduced into host cells, such as T cells, and the cells can be used in immunotherapy for the treatment of various cancers.
Owner:FRED HUTCHINSON CANCER RESEARCH CENTER
Isolated peptides and uses thereof
InactiveUS20100297011A1Enhanced interactionStructure miniaturizationOrganic active ingredientsBacteriaPreproinsulinType 1 diabetes
The present invention provides isolated preproinsulin-derived peptides of 8 or 9 amino acids, comprising the amino acid sequence WGPDPAA (SEQ ID NO: 1), isolated Class I peptide-HLA complexes presenting said peptides and isolated molecules having binding affinity for said peptides and / or said peptide-HLA complexes. Such compositions are useful in the treatment of Type 1 diabetes mellitus (T1DM).
Owner:KINGS COLLEGE LONDON
Binding molecules for PIWIL1 peptide-HLA complexes
The present invention relates to binding molecules comprising a T-cell receptor (TCR) variable domain capable of binding to a PIWIL1 peptide-HLA complex. The present invention also relates to the use of such molecules for the treatment of malignant diseases.
Owner:IMMUNOCORE LTD
Allogeneic human macrophages for cell therapy
The present invention relates to an allogeneic myeloid cell, such as a macrophage, for use in therapy, such as the treatment of cancer in a human patient, wherein the allogeneic myeloid cell, such as an allogeneic macrophage, comprises at least one MHC-II complex identical to any one MHC-II complex of the human patient. This advantage is that an antigen-specific reaction of CD4 + T cells of the human patient, for example, against tumor neoantigens, can be initiated. The present invention also relates to an allogeneic myeloid cell, such as an allogeneic macrophage or an allogeneic monocyte, for use in the treatment of cancer in a human patient wherein the allogeneic macrophage or the allogeneic monocyte comprises at least one protein complex selected from the group consisting of HLA-DR, HLA-DP and HLA-DQ, said protein complexes are identical to any corresponding HLA complex of said human patient, preferably wherein the allomacrophages comprise two protein complexes selected from said group, or even wherein the allomacrophages comprise three complexes selected from said group.
Owner:TECHNISCHE UNIVERSITAT DRESDEN
Targeted KRAS mutation TCR molecule and cell and application thereof
A binding protein is provided comprising a binding domain having antigen specificity for an antigen peptide: HLA complex, the binding domain comprising a T cell receptor (TCR) alpha chain variable region and a TCR beta chain variable region. Also provided are uses of the binding protein and a pharmaceutical composition comprising the binding protein in the treatment of cancers associated with the antigen peptide.
Owner:BEIJING DCTY BIOTECH CO LTD
Binding molecules against prame peptide-HLA complexes
The present invention relates to a binding molecule comprising a T cell receptor (TCR) variable domain and capable of binding a PRAME peptide-HLA complex. In particular, the present invention relates to a binding molecule capable of binding to PYLGQMINL (SEQ ID NO: 1) complexed with HLA-A24. The invention also relates to the use of these molecules in the treatment of malignant diseases.
Owner:IMMUNOCORE LTD
TCR molecules and cells targeting KRAS mutations and uses thereof
The present invention provides a binding protein having antigen specificity for an antigenic peptide / HLA complex, comprising a binding domain containing a T cell receptor (TCR) α chain variable region and a TCR β chain variable region, and uses of the binding protein and pharmaceutical compositions containing the binding protein in the treatment of cancers associated with the antigenic peptide.
Owner:BEIJING DCTY BIOTECH CO LTD
Binding proteins specific for ras neoantigens and uses thereof
PendingUS20250177531A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyPeptide antigenCancer prevention
The present disclosure provides compositions and methods for targeting a Ras antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as T cell receptors bind to a Ras antigen:HLA complex.Disclosed binding proteins are highly sensitive to antigen, capable of inducing activation of host T cells at low concentrations of peptide antigen. In certain embodiments, binding proteins of the present disclosure are non-alloreactive against, are substantially non-alloreactive against, and / or have a low risk of alloreactivity against (i) amino acid sequences from the human proteome and / or (ii) against human HLA alleles. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers.
Owner:FRED HUTCHINSON CANCER CENT
Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy
The present invention is directed to the field of immunotherapy, in particular, adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer. The invention provides a nucleic acid encoding at least one TCR alpha or beta chain construct of a TCR construct capable of specifically binding to a MYD88 L265P peptide of SEQ ID NO: 2 in the context of HLA-B*07:02 having a high avidity to said peptide / HLA complex. The invention also provides corresponding proteins and host cells, preferably, CD8+ T cells, as well as the medical use of such nucleic acids, proteins or host cells, in particular, in the diagnosis, prevention and / or treatment of a MyD88 L265P expressing cancer such as a non-Hodgkin B-cell lymphoma selected from the group comprising diffuse large B-cell lymphoma (DLBCL), e.g., activated B-cell-like DLBCL (ABC-DLBCL) or pCNS DLBCL, cutaneous DLBCL, leg-type DLBCL or testicular DLBCL; lymphoplasmacytic lymphoma (LPL), e.g., Waldenstrom macroglobulinemia (WM); and IgM monoclonal gammopathy (IgM MGUS).
Owner:CHARITE UNIVS MEDIZIN BERLIN
Binding protein specific for neoantigen, engineered cell, and use thereof
The present disclosure provides compositions and methods for targeting neoantigens, for example, to treat or prevent cancer. Embodiments disclosed include binding proteins that bind to neoantigen:HLA complexes, such as T cell receptors. The binding proteins further include a fusion protein of a CD95 ectodomain and a CD137 intracellular signaling domain (Fas-41BB), and a construct comprising a CDS coreceptor α or β chain. The disclosed binding proteins are sensitive to antigens and can induce activation of host T cells with low concentrations of peptide antigens. In certain embodiments, the binding proteins of the present disclosure are (i) non-alloreactive, substantially non-alloreactive, and / or have a low risk of alloreactivity against amino acid sequences derived from the human proteome and / or (ii) human HLA alleles. Polynucleotides encoding such binding proteins can be introduced into host cells, such as T cells, and the cells can be used in immunotherapies for treating various cancers.
Owner:AFFINITY THERAPEUTICS INC +1
Method of making a personalized cancer vaccine
A method of making a personalized cancer vaccine is disclosed. The method includes predicting whether a first neoantigen or a second neoantigen of an individual cancer patient has a stronger binding affinity for a human leukocyte antigen (HLA) complex of the patient and creating a particle containing the neoantigen with the stronger predicted binding affinity. The predicting step can be implemented using artificial intelligence, statistical modeling, or a combination thereof. Particles are created by encapsulating the neoantigen with the stronger predicted binding affinity for the HLA complex of the patient in a biocompatible material. Placing the antigen in a particular sized particle is referred to here as Size Exclusion Antigen Presentation Control, (SEAPAC) used in methods of treating the patient using such a personalized cancer vaccine.
Owner:FLOW PHARMA
A NY-ESO-1 TCR and its application
The present invention belongs to the technical field of tumor immunotherapy, discloses a NY-ESO-1TCR and its application, and specifically discloses a TCR variant, comprising an α chain variable region and a β chain variable region, wherein the α chain variable region is obtained by replacing at least one amino acid with the amino acid shown in SEQ ID NO:2; and / or the β chain variable region is obtained by replacing at least one amino acid with the amino acid shown in SEQ ID NO:4. The TCR variant provided by the present invention is mainly obtained by introducing various mutations into the natural 1G4TCR as a template. The TCR variant of the present invention can bind to a variety of SLLMWITQC-HLA complexes. After the TCR variant of the present invention is constructed to form TCR T in T cells, better anti-tumor effects are exhibited, and it has good application prospects.
Owner:GUANGZHOU FINELMMUNE BIOTECHNOLOGY CO LTD
T cell receptor specifically binding to HER2-derived peptide fragment and application thereof
ActiveCN121471339AImmunoglobulin superfamilyGenetically modified cellsEffector cellCellular receptor
The invention relates to the technical field of biological medicines, in particular to a T cell receptor specifically bound with an HER2 (human epidermal growth factor receptor) source peptide fragment and application of the T cell receptor. The T cell receptor specifically bound with the HER2 source peptide fragment comprises an alpha chain variable region and a beta chain variable region, and the sequence of the HER2 source peptide fragment is KIFGSLAFL. The TCR provided by the invention can specifically recognize and combine with an HER2 peptide-HLA compound presented by tumor cells so as to mediate accurate killing of effector T cells on the tumor cells.
Owner:BEIJING LIKANG LIFE SCIENCES & TECH CO LTD